224817-00-9

Usage

Potential biological activities

antimicrobial and anticancer properties
Acts as an inhibitor of p300, a histone acetyltransferase
Used as a reagent in organic synthesis
Potential applications in treating various types of cancer
Continues to be studied for its pharmacological properties.

Upstream product

• 5326-23-8 6-Chloro-3-pyridinecarboxylic acid 
• 58757-38-3 6-Chloronicotinoyl chloride 
• 95-53-4 o-toluidine 

Downstream Products

• 1258161-42-0 6-(3,4-dihydro-1H-isoquinoline-2-yl)-N-methyl-N-(2-methylphenyl)nicotinamide 
• 1258161-09-9 6-(3,4-dihydro-1H-isoquinoline-2-yl)-N-o-tolylnicotinamide 

Relevant academic research and scientific papers

SAR based design of nicotinamides as a novel class of androgen receptor antagonists for prostate cancer

Molecular knowledge of pure antagonism and systematic SAR study offered a direction for structural optimization of DIMN to provide nicotinamides as a novel series of AR antagonists. Nicotinamides with extended linear scaffold bearing sterically bulky alkoxy groups on isoquinoline end were synthesized for H12 displacement. AR binding affinity and molecular basis of antiandrogenic effect establish the optimized derivatives, 7au and 7bb, as promising candidates of second generation AR antagonists for advanced prostate cancer.

NEW NICOTINAMIDE DERIVATIVES WITH ANTI-ANDROGEN EFFECTS, PROCESSES OF PREPARING, AND ANTIANDROGENS COMPRISING THE SAME

Provided are novel nicotinamide derivatives and pharmaceutically acceptable salts thereof with anti-androgen effects, preparing processes of the same and antiandrogens containing the same as active ingredients. More particularly, the said nicotinamide derivatives have anti-androgen activity, so that they can be effectively used as a preventive or therapeutic agent for androgen-related diseases such as prostatic disease, androgenic alopecia and acne.

Substituted pyridine compounds and methods of use

Selected novel substituted pyridine compounds are effective for prophylaxis and treatment of diseases, such as TNF- alpha , IL-1 beta , IL-6 and/or IL-8 mediated diseases, and other maladies, such as pain and diabetes. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving inflammation, pain, diabetes, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.